Faculty

Hannah M. Linden, MD

Hannah M. Linden, MD FACP

Associate Professor
Department of Medicine
Division of Oncology

Mailing Address

Seattle Cancer Care Alliance
825 Eastlake Avenue W
Seattle WA 98109-1023 G3-630

Admin Contact

Audrey Monroe
206.288.6989
amonroe@seattlecca.org
Fax: 206.288.2054

Specialty / Expertise

  • Breast Oncology
  • Patient Navigation

Research Interests

  • Understanding resistance and sensitivity to endocrine therapy of breast cancer, and identification of methods to overcome resistance
  • Pharmacodynamic imaging
  • Improving access to clinical trials
  • Improving outcomes for vulnerable populations

Current Research Projects

Title: Measures of Endocrine Sensitivity in Early Breast Cancer
Funding Source: NIH/NCI
The primary objective is to examine dynamic tumor characteristics by imaging and tissue analysis in a brief preoperative two week window study to define AI sensitive tumors and establish a rapid method for identification of whether this ER-targeted therapy is active at the tumor’s molecular target.

Title: Pharmacodynamic and Tissue Measures of Early Breast Cancer Endocrine Sensitivity
Funding Source: Susan G. Komen for the Cure
The primary objective is to examine dynamic tumor characteristics by imaging and tissue     analysis in a brief, preoperative, two-week window study in premenopausal women to determine  sensitivity to complete hormonal blockade and establish a rapid method for identification of whether this ER-targeted therapy is active at the tumor’s molecular target.

Title: Early Assessment of Response to Targeted Therapy in Breast Cancer
Funding Source: Avon-NCI
The objectives are to determine whether the percent change in FDG-PET standardized uptake
value and percent change in cell proliferation as assessed by tumor biopsy over the first
two weeks of either hormonal therapy or trastuzumab-based therapy are associated with tumor response.

Title: Survivorship Center Grant
Funding Source: Lance Armstrong Foundation
To create a comprehensive survivorship program with outreach to cancer patients throughout the lifespan, treated with conventional therapy or transplantation; 2) to develop stronger community resources, targeting currently underserved populations; 3) to establish and evaluate unique models of care designed to overcome barriers to optimal health services and access to research for survivors

Title: Partnering With Patients to Improve Breast Cancer Care – Year 4
Funding Source: Susan G. Komen for the Cure (Puget Sound Affiliate)
This proposal continues to develop a patient navigator program and assist patients getting to multiple sites of care and improve the care for vulnerable patients.

Title: Advanced PET-CT Imaging for Improving Clinical Trials
Funding Source: NCI/NIH
The goal is to improve cancer clinical trials by enhancing the effectiveness of quantitative PET/CT imaging of tumor response.

Training

Dr. Linden received her BA from Yale University, New Haven, CT and her MD from University of Massachusetts Medical School, Worcester, MA. She completed her Internal Medicine Residency at the University of Arizona, Tucson, AZ, and completed her fellowship and postdoctoral training in Hematology and Oncology at the University of Washington, Seattle, WA.

Selected Publications

Linden H, Kaushansky K:  The glycan domain of thrombopoietin enhances its secretion. Biochemistry 39(11):3044-51, 2000.

Linden H, Kaushansky K:  The glycan domain of thrombopoietin (TPO) acts in trans to enhance secretion of the hormone and other cytokines.  J Biol Chem 277(38):35240-7, 2002.

Agoff SN, Swanson PE, Linden HM, Hawes SE, Lawton TJ.  Androgen receptor expression in estrogen receptor negative breast cancer:  Immunohistochemical, Clinical, and Prognostic Associations.  Am J Clin Pathl 120(5):725-31, 2003.

Linden HM, Ramsey S, Anderson N: An ounce of prevention or a pound of cure? Investing to Improve Breast Cancer Outcomes for African American Women. J Clin Oncology 22(13):2517-2518, 2004, Invited editorial

Elmore JG, Nakano CY, Linden HM, Reisch LM, Ayanian JZ, Larson EB: Racial inequities in the timing of breast cancer detection, diagnosis and initiation of treatment. Med Care.  2005 43(2): 141-148.

Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Lawton TJ, Barlow WE Schubert EK, Mankoff DA.  Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival. Cancer 103(4):680-688, 2005.

Oestreicher N, Veenstra DL, Linden HM, McCune JS, Ramsey SD:  The cost of adjuvant chemotherapy in early stage breast carcinoma. Cancer. 2005, 104(10):2054-62.

Oestreicher N, Ramsey SD, Linden HM, McCune JS, Van’t Veer LJ, Burke W, Veenstra DL. Gene Expression Profiling and Breast Cancer Care: What are the potential benefits and policy implications? Genet Med 2005 Jul-Aug; 7(6):380-9.

Specht JM, Tam SL, Kurland BF, Gralow JR, Livingston RB, Linden HM, Ellis GK, Schubert EK, Dunwald LK, Mankoff DA.  Serial 2-[18F] flouro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).  Published on line, February 1st, 2006, Breast Cancer Res Treatment.

Linden HM, Krohn KA, Livingston RB, Mankoff D.  Monitoring targeted therapy:  Is fluorodeoxylucose (FDG) uptake a marker of early response?  Invited editorial.  Clin Cancer Res. 2006 Oct 1;12(19):5608-5610.

Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, Petra P, Peterson LM, Schubert E, Dunnwald LK, Krohn KA, Mankoff DA.  Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment.  J Clin Oncol 2006 24(18): 2793-2799.

Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, Doot RK, Lawton TJ, Barlow WE, Kurland BF, Schubert EK.  Tumor Metabolism and Blood Flow Changes by PET – Relation to Survival among a Prospective Cohort of Neoadjuvantly Treated Locally Advanced Breast Cancer Patients.  J Clin Oncol 2007, #154385. 

Linden HM, Haskell CM, Green SJ, Osborne CK, Sledge, Jr. GW, Shapiro CL, Ingle JN, Lew D, Hutchins LF, Livingston RB, Martino S. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313). J Clin Oncol 2007 Feb 20; 25(6):656-661.
[PubMed Abstract]

Linden HM, Reisch LM, Nakano C, Harrington M, Jackson C, Hart A, Elmore JG.   Attitudes toward participation in breast cancer screening and randomized clinical trials in the African American community: a focus group study. Cancer Nursing 2007 30(2):1-10.

Krohn KA. O’Sullivan F, Crowley J, Eary JF, Linden HM, Link JM, Mankoff DA, Muzi M, Rajendran JG, Spence AM, Swanson KR. Challenges in Clinical Studies with Multiple Imaging Probes. Nucl Med Bio. 2007 Oct,34(7):879-85 Review

Ramsey SD, Zeliadt SB, Richardson LC, Pollack L, Linden HM, Blough D, Anderson N.  Disenrollment from Medicaid after recent cancer diagnosis?  Medical Care.  2008 Jan;46(1):49-57.

Linden HM, Jackson C.  Ending cancer treatment disparities.  Seattle Post-Intelligencer NW Source/guest editorial 349983.  February 4, 2008.

Mankoff DA, Link JM, Linden HM, Sundararajan L, Krohn KA.  Tumor Receptor Imaging.  J Nucl Med.  2008 June; 49(6):149S-163S

Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, Doot RK, Lawton TJ, Barlow WE, Kurland BF, Schubert EK, Mankoff DA.  Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 2008 Sep 20;26(27):4449-57.
[PubMed Abstract]

Ramsey SD, Zeliadt SB, Richardson LC, Pollack LA, Linden HM, Blough DK, Keitheri Cheteri M, Tock L, Nagy K, Anderson N. Discontinuation of Radiation Treatment among Medicaid-Enrolled Women with Local and Regional Stage Breast Cancer. The Breast Journal (in press).

Specht JM, Kurland BF, Montgomery S, Dunnwald L, Doot R, Gralow JR, Ellis GK, Linden HM, Livingston RB, Allison K, Schubert E, Mankoff DA.  Tumor metabolism and blood flow as assessed by PET varies by tumor subtype in locally advanced breast cancer. Clin Cancer Res May 15, 2010 16:2803-2810.

Last updated: June 2010

Top